John Cogan, Head of Innovation, shares his views on what R&D functions should be focusing on to maximise Artificial Intelligence opportunities.
After reading with interest a recent Times article outlining the role that robots are playing in helping transform the healthcare sector, it’s clear that the gains could be enormous.
With androids aiding surgeons in operating theatres and artificial intelligence systems scanning x-rays, the bar is being set very high with machines pooling the medical expertise of thousands of specialists.
The growing maturity of artificial intelligence technologies, including natural language processing, machine learning and natural language generation is already leading cutting-edge Life Sciences companies to investigate their possibilities in R&D.
We expect to see more proofs of concept and targeted deployments of these technologies across the whole spectrum of R&D functions and processes including market access, clinical trial recruitment, automation of adverse event capture and processing, automation of report writing, translation automation and enhanced Regulatory Intelligence services.
Life Sciences should be looking at the opportunity to eliminate unnecessary work, drastically cut cycle times and the possibility of reducing operational costs by 50% or more. At full maturity, these innovations have the potential to completely transform the operations and cost base for both Life Sciences R&D and the growing Service Provider community.